Omalizumab and mast cell disorders: are we there yet?
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Response to additional drugs, including multitargeted tyrosine kinase inhibitors (in patients with SM, such as midostaurin) and anti-IgE therapy (omalizumab), may be considered an indirect sign of MCA or MCAS.
“Response to additional drugs, including multitargeted tyrosine kinase inhibitors (in patients with SM, such as midostaurin) and anti-IgE therapy (ie, omalizumab) may be considered an indirect sign of MCA or MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [86]
Cites
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172 · see citing works
Lowe, P. J., Tannenbaum, S. J., Gautier, A., & Jimenez, P. A. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03401.x · Cited by 167 · see citing works
Mastocytosis and insect venom allergy
Bonadonna, P., Zanotti, R., & Müller, U. (2010) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32833b280c · Cited by 125 · see citing works
Broesby‐Olsen, S., Vestergaard, H., Mortz, C. G., Jensen, B., Havelund, T., Hermann, A. P., Siebenhaar, F., Møller, M. B., Kristensen, T. K., Bindslev‐Jensen, C., et al. (2018) · Allergy · doi:10.1111/all.13237 · Cited by 112 · see citing works
Kontou-Fili, K. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01604.x · Cited by 98 · see citing works
Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS
Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.039 · Cited by 70 · see citing works
Sokol, K. C., Ghazi, A. I., Kelly, B. C., & Grant, J. A. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.03.009 · Cited by 69 · see citing works
Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases
Molderings, G. J., Raithel, M., Kratz, F., Azémar, M., Haenisch, B., Harzer, S., & Homann, J. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4640 · Cited by 63 · see citing works
Kontou-Fili, K., & Filis, C. I. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02045.x · Cited by 54 · see citing works
Brownell, J., & Casale, T. B. (2004) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2004.06.002 · Cited by 38 · see citing works
Anti-IgE Treatment for Disorders Other Than Asthma
Stokes, J. R. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00152 · Cited by 23 · see citing works
Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair ® )
Hughes, J. D. M., Olynych, T., Chapdelaine, H., Segal, L., Miedzybrodzki, B., & Ben‐Shoshan, M. (2018) · Clinical and Experimental Dermatology · doi:10.1111/ced.13408 · Cited by 23 · see citing works
Paraskevopoulos, G., Sifnaios, E., Christodoulopoulos, K., Mantopoulou, F., Papakonstantis, M., & Sabaziotis, D. (2013) · PubMed · Cited by 20 · see citing works
Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis
Constantine, G. M., Bressler, P. B., Petroni, D., Metcalfe, D. D., & Carter, M. C. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.07.041 · Cited by 20 · see citing works
The efficacy of omalizumab in Cutaneous Mastocytosis: A case series
Hinojosa, T., Lewis, D. J., Vangipuram, R., Safeer, L. Z., Mui, U. N., Haley, C. T., Konoplev, S. N., & Tyring, S. K. (2019) · Dermatologic Therapy · doi:10.1111/dth.12848 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83 · see citing works
“Response to additional drugs, including multitargeted tyrosine kinase inhibitors (in patients with SM, such as midostaurin) and anti-IgE therapy (ie, omalizumab) may be considered an indirect sign of MCA or MCAS.(80-88) Agents targeting growth and activation of neoplastic MCs, such as KIT-targeting kinase blockers, ar…”
BackgroundImpact of Biologic Therapy on the Small Airways Asthma Phenotype
Chan, R., & Lipworth, B. J. (2022) · Lung · doi:10.1007/s00408-022-00579-2 · Cited by 44 · see citing works
Jennings, S. V., Finnerty, C. C., Hobart, J. S., Martín‐Martinez, M., Sinclair, K. A., Slee, V. M., Agopian, J., Akin, C., Álvarez‐Twöse, I., Bonadonna, P., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.06.018 · Cited by 12 · see citing works
Kim, K., Kim, J.-O., & Park, S. G. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04557-3 · Cited by 9 · see citing works
Kounis, N. G., Koniari, I. C., Tsigkas, G., & Davlouros, P. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.008 · Cited by 9 · see citing works
Bossi, G., Brazzelli, V., AMICI, M. D., Pietra, D., Raviola, C., Naso, M., Regalbuto, C., Boselli, F., Fortina, V., & Marseglia, G. L. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01402-7 · Cited by 7 · see citing works
Complete relief by omalizumab in eruptive pruritic papular porokeratosis
Jia, H., Xue, R., & Ran, L. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.04.030 · Cited by 4 · see citing works
Park, S. G., Kim, K., & Kim, J.-O. (2022) · Research Square · doi:10.21203/rs.3.rs-1387055/v1 · Cited by 1 · see citing works
Cakmak, M. E., & Öztop, N. (2026) · Journal of Asthma · doi:10.1080/02770903.2026.2721175
- Authors
- Weiler, C. R.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Weiler, Catherine R.
- Venue
- The Journal of Allergy and Clinical Immunology In Practice
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 7
- Issue
- 7
- Pages
- 2396-2397
- ISSN
- 2213-2198 (ISSN-L)
- OpenAlex
- W2971582433
- Cited by
- 9
- References
- 15
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 1 · 2020: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Allergy and Clinical Immunology In Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- omalizumab, mast cell disease, IgE, FcεRI receptor, allergic asthma, chronic spontaneous urticaria, off-label drug use, anti-IgE therapy
- MeSH terms
- Omalizumab, Humans, Mast Cells, Mastocytosis, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
